Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.

Matthew StargardterAli McBride Jon ToshRameet SachdevMo YangApoorva AmbavaneMadhav MittalHelene VioixFrank Xiaoqing Liu

Published in: Journal of medical economics (2021)

The estimated budgetary impact of tepotinib for the treatment of adult patients with mNSCLC harboring METex14 skipping alterations is minimal from the perspective of US health plans.

Keyphrases

healthcare
mental health
combination therapy
health insurance
social media
health information
climate change
childhood cancer